89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
February 21, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Provides Business Update and Outlook for 2023
January 04, 2023 16:01 ET
|
89bio, Inc.
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of...
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
December 12, 2022 18:30 ET
|
89bio, Inc.
– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver...
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 16:05 ET
|
89bio, Inc.
-Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023- -Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of...
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
November 05, 2022 13:00 ET
|
89bio, Inc.
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in...
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
October 13, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022
August 26, 2022 06:00 ET
|
89bio, Inc.
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver...
89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH
August 18, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...